7 July, 2017
Annals of Noninvasive Electrocardiology recently published a paper on KOS effect on the Autonomic Nervous System (ANS).This was a sub-analysis from a Safety Study performed at the Karolinska Trial Alliance. ECGs were evaluated by iCardiac in the US, and findings were that KOS treatment had an effect on Heart Rate Variability (HRV) as a sign of effect on the ANS.
Results from the Safety Study in summary:• It can be concluded that KOS has an effect on the autonomic balance with pronounced heart-rate independent reduction on HRV. Treatment with the Chordate system was demonstrated to be safe and well tolerated.• Pulmonary function as assessed by spirometry was unaffected by the KOS treatment.• Blood pressure and pulse rate were unaffected by the treatment.• Assessment of heart rate variability using Holter-ECG recordings demonstrated a significant and reversible reduction in time domain variability during treatment without concomitant effect on heart rate.• There were no treatment related effects on hematology, coagulation or clinical chemistry variables.
Link to clinical paperhttp://onlinelibrary.wiley.com/doi/10.1111/anec.12474/pdf/
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.